Positron emission tomography and brain monoamine neurotransmission -: Entries for study of drug interactions

被引:19
作者
Hartvig, P [1 ]
Bergström, M [1 ]
Antoni, G [1 ]
Långström, B [1 ]
机构
[1] Univ Uppsala, PET Ctr, Univ Hosp, S-75185 Uppsala, Sweden
关键词
positron emission tomography; neurotransmission; dopamine; serotonin;
D O I
10.2174/1381612023394458
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Monoamine neurotransmission is a complicated process with interactions between individual neurotransinitter pathways, multiple receptors with different responses and a variety of feedback loops regulating neurotransmitter synthesis, release, reuptake and effect on receptors. The system is further affected by a range of enzymes with co-factors controlling synthesis and degradation of monoamines. Positron emission tomography (PET) has evolved to a very versatile tool for the in vivo imaging and characterisation of physiology and biochemistry. The basis for its expansion during the last years has been a rapid development of labelling methods, allowing a range of tracer molecules to be generated and used in human and research animal Studies. The most important PET radionuclide is C-11 with a short half-life of approximately 20 minutes. This radionuclide is ideal for the labelling of organic molecules and for multitracer applications in research and drug development studies. PET has been used for a range of explorative studies on the monoamine neurotransmission, as exemplified by studies on the expression of dopamine and serotonin receptors as well as the rate of dopamine and serotonin synthesis. The present article gives examples of studies where PET has been used for the characterization of monoamine transmitter systems in experimental animals and in humans, both in healthy individuals and in patients with diseases affecting neurotransmission.
引用
收藏
页码:1417 / 1434
页数:18
相关论文
共 83 条
[21]   SUBSTITUTED BENZAMIDES AS LIGANDS FOR VISUALIZATION OF DOPAMINE RECEPTOR-BINDING IN THE HUMAN-BRAIN BY POSITRON EMISSION TOMOGRAPHY [J].
FARDE, L ;
EHRIN, E ;
ERIKSSON, L ;
GREITZ, T ;
HALL, H ;
HEDSTROM, CG ;
LITTON, JE ;
SEDVALL, G .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1985, 82 (11) :3863-3867
[22]   QUANTITATIVE-ANALYSIS OF D2 DOPAMINE RECEPTOR-BINDING IN THE LIVING HUMAN-BRAIN BY PET [J].
FARDE, L ;
HALL, H ;
EHRIN, E ;
SEDVALL, G .
SCIENCE, 1986, 231 (4735) :258-261
[23]   Brain function in a patient with torture related post-traumatic stress disorder before and after fluoxetine treatment:: a positron emission tomography provocation study [J].
Fernandez, M ;
Pissiota, A ;
Frans, Ö ;
von Knorring, L ;
Fischer, H ;
Fredrikson, M .
NEUROSCIENCE LETTERS, 2001, 297 (02) :101-104
[24]  
Fernell E, 1997, DEV MED CHILD NEUROL, V39, P313
[25]   [11C]NNC 22-0215, a metabolically stable dopamine D1 radioligand for PET [J].
Foged, C ;
Halldin, C ;
Swahn, CG ;
Ginovart, N ;
Karlsson, P ;
Lundkvist, C ;
Farde, L .
NUCLEAR MEDICINE AND BIOLOGY, 1998, 25 (05) :503-508
[26]   MECHANISTIC POSITRON EMISSION TOMOGRAPHY STUDIES - DEMONSTRATION OF A DEUTERIUM-ISOTOPE EFFECT IN THE MONOAMINE OXIDASE-CATALYZED BINDING OF [C-11] L-DEPRENYL IN LIVING BABOON BRAIN [J].
FOWLER, JS ;
WOLF, AP ;
MACGREGOR, RR ;
DEWEY, SL ;
LOGAN, J ;
SCHLYER, DJ ;
LANGSTROM, B .
JOURNAL OF NEUROCHEMISTRY, 1988, 51 (05) :1524-1534
[27]   MAPPING HUMAN-BRAIN MONOAMINE OXIDASE-A AND OXIDASE-B WITH C-11 LABELED SUICIDE INACTIVATORS AND PET [J].
FOWLER, JS ;
MACGREGOR, RR ;
WOLF, AP ;
ARNETT, CD ;
DEWEY, SL ;
SCHLYER, D ;
CHRISTMAN, D ;
LOGAN, J ;
SMITH, M ;
SACHS, H ;
AQUILONIUS, SM ;
BJURLING, P ;
HALLDIN, C ;
HARTVIG, P ;
LEENDERS, KL ;
LUNDQVIST, H ;
ORELAND, L ;
STALNACKE, CG ;
LANGSTROM, B .
SCIENCE, 1987, 235 (4787) :481-485
[28]   Time course of central nervous dopamine-D2 and 5-HT2 receptor blockade and plasma drug concentrations after discontinuation of quetiapine (Seroquel®) in patients with schizophrenia [J].
Gefvert, O ;
Bergström, M ;
Långström, B ;
Lundberg, T ;
Lindström, L ;
Yates, R .
PSYCHOPHARMACOLOGY, 1998, 135 (02) :119-126
[29]   D2 and 5HT2A receptor occupancy of different doses of quetiapine in schizophrenia:: a PET study [J].
Gefvert, O ;
Lundberg, T ;
Wieselgren, IM ;
Bergström, M ;
Långström, B ;
Wiesel, FA ;
Lindström, L .
EUROPEAN NEUROPSYCHOPHARMACOLOGY, 2001, 11 (02) :105-110
[30]  
Halldin C, 1998, J NUCL MED, V39, P2061